Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Exceptional Losses:...

    Exceptional Losses: Fortis reports consolidated net loss of Rs 180 crore for December quarter

    GarimaWritten by Garima Published On 2019-02-15T12:41:41+05:30  |  Updated On 15 Feb 2019 12:41 PM IST
    Exceptional Losses: Fortis reports consolidated net loss of Rs 180 crore for December quarter

    Commenting on the results, Fortis Healthcare Chairman Ravi Rajagopal said the last quarter witnessed the reconstitution of the Board, with the appointment of five IHH nominees along with existing three independent directors.


    New Delhi: Fortis Healthcare on Wednesday reported a consolidated net loss of Rs 180.11 crore for the quarter ended December 31, 2018, mainly on account of exceptional losses.


    The company had posted a net loss of Rs 19.10 crore for the corresponding period of the previous fiscal, Fortis Healthcare said in a filing to BSE.


    Consolidated revenue from operations of the company stood at Rs 1,103.27 crore for the quarter as against Rs 1,120.65 crore for the same period year ago.


    Net profit for the third quarter of this fiscal year was primarily impacted by exceptional losses. These primarily pertain to impairments related to the goodwill and of certain assets, Fortis Healthcare said.


    These in addition, also include certain one-off financial and legal expenses related to advisory fees for corporate transactions, it added.


    Commenting on the results, Fortis Healthcare Chairman Ravi Rajagopal said the last quarter witnessed the reconstitution of the Board, with the appointment of five IHH nominees along with existing three independent directors.


    "Going forward the association will prove to be synergetic and help us chart the next phase of growth for the organisation," he added.


    Also Read: DISMAL report: Fortis reports a net loss for Sept, Dec quarters


    During the earnings call, Rajagopal said, "Following the Luthra investigation report which we then filed with various authorities we have over the last six, seven months completely severed all links with the former promoters. We have started pursuing legal and other means for recovery of all dues to Fortis."


    Following the Sebi order of October 2018 where clear directive to us was to cease any direct or indirect dealings with the former promoters, we have done exactly that, he added.


    Fortis Healthcare CEO Bhavdeep Singh said that with the partnership of IHH and the completion of RHT acquisition, "we are confident of a progressive improvement in our performance in the ensuing quarters."


    The company had net cash of Rs 2,359 crore as on December 31, 2018, compared to a net debt of Rs 1,497 crore on September 30, 2018, and net debt of Rs 1,339 crore on December 31, 2017, the company said.


    The company also said its board has approved the appointment of Vivek Kumar Goyal as Chief Financial Officer of the company. The effective date of appointment shall be on or before May 1, 2019.


    Also Read: Fortis Healthcare reports a Q4 net loss at Rs 37.52 crore, Check out details

    Bhavdeep Singhceo Vivek Kumar GoyalFHLFHL newsFinancial resultsFortisFortis CEOfortis fiscal 2019fortis FY 2019Fortis HealthcareFortis HospitalsFortis lossFortis Q3hospital newsHospital news in IndiaIHHindian hospital newsnet lossQ3Vivek Kumar Goyal
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok